Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624858 · ClinicalTrials.gov registry record · Phase 2
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
A Phase 2 study of Depression, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00624858: Completed Phase 2 study of Depression, sponsored by Orexigen Therapeutics.
NCT00624858 is a Phase 2 study of Depression that has completed, run by Orexigen Therapeutics. The registered enrollment target is 25 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00624858, a Phase 2 study of Depression, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
Conditions Studied
Interventions
- DRUG naltrexone SR 32 mg/ bupropion SR 360 mg daily
Study Locations (1)
Ohio
- Lindner Center of HOPE - Mason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00624858 record still lists
NCT00624858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which naltrexone SR 32 mg/ bupropion SR 360 mg daily is the first listed.
NCT00624858 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00624858 about?
NCT00624858 is a clinical study titled "A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression". The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
What is the current status of trial NCT00624858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-01. Estimated completion is 2009-07.
What conditions does trial NCT00624858 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00624858?
The interventions under investigation include: naltrexone SR 32 mg/ bupropion SR 360 mg daily (DRUG).
Who is sponsoring clinical trial NCT00624858?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00624858 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00624858's enrollment target sits among peer trials
25 587th of 679 higher than 87 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia